NextPlat Corp Updates Improved Cash Flow And Operational Profitability Goals For 2026 Supported By Early Q1 Momentum In High-Margin 340B; Says Q4 2025 340B Revenue Is Expected To Increase By More Than 90% Compared To Q3 2025

Improved Cash Flow and Operational Profitability Goals for 2026 Supported by Early Q1 Momentum in High-Margin 340B, Expansion of Higher-Margin Contracted Services, and Continued Growth in E-Commerce Revenue

HALLANDALE BEACH, Fla., Feb. 25, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that it expects to report sequential improvement in key financial and operational metrics for the fourth quarter ended December 31, 2025 compared to the third quarter, reflecting continued progress from its strategic business refocusing initiatives and increasing contribution from higher-margin revenue streams. These results are preliminary and subject to completion of the Company's year-end audit and may change.

As previously communicated in the Company's third quarter 2025 earnings report and subsequent business update, successful ongoing business refocusing and development activities conducted over the past six months have begun contributing to meaningful sequential progress against growth, cost reduction and profitability objectives. Key financial metrics include:

• Healthcare Operations Revenue Improvement: Fourth quarter 2025 340B revenue is expected to increase by more than 90% compared to the third quarter of 2025, driven by direct engagement initiatives and operational improvements with existing 340B customers. Total prescription volume is anticipated to increase approximately 7% sequentially, reflecting growth in contracted prescription activity. Although total prescription volumes may fluctuate in 2026 as the Company continues to shift towards more contracted services, it is already experiencing improved unit economics driven by a focus on revenue quality, cost discipline, and the impact of the Medicare manufacturer rebate program, supporting overall margin expansion.
• Gross Margin Improvement: Consolidated gross margin in the fourth quarter of 2025 is expected to remain relatively consistent with the third quarter of 2025. As a result of its continued shift towards higher margin contracted services in its healthcare operations including growth in 340B and medication fulfilment contracts, the Company anticipates significant consolidated gross margin expansion in the range of 20%-25% in the first quarter of 2026 with incremental improvement expected throughout 2026.
• Operational Process Efficiency and Cost Reduction: As previously communicated in our CEO Shareholder Update Letter, the Company anticipates sustained reductions in annual operating expenses driven by structural overhead initiatives, including the closing of underutilized office space, personnel consolidation, reduced reliance on external consultants, and enhanced logistics efficiencies.
• Solid Liquidity: The Company's operations continue to be supported by a solid balance sheet with a cash balance of approximately $13 million, working capital of approximately $15 million, and zero unsecured debt expected as of December 31, 2025.
• On Track for Improved Operating Results in First Half of 2026: Preliminary results through the first quarter of 2026 indicate continued strong growth in profitable 340B and contracted fulfillment revenue, combined with ongoing operational efficiencies, supporting management's expectation of meaningful reductions in operating losses by the end of the second quarter of 2026.